PMID- 23545290
OWN - NLM
STAT- MEDLINE
DCOM- 20131022
LR  - 20141120
IS  - 1878-5905 (Electronic)
IS  - 0142-9612 (Linking)
VI  - 34
IP  - 20
DP  - 2013 Jul
TI  - Functional recovery of urethra by plasmid DNA-loaded injectable agent for the 
      treatment of urinary incontinence.
PG  - 4766-76
LID - S0142-9612(13)00355-4 [pii]
LID - 10.1016/j.biomaterials.2013.03.045 [doi]
AB  - Stress urinary incontinence (SUI) is an embarrassing problem affecting a large 
      number of women and interfering with their quality of life. The injury or 
      weakness of urethral supporting tissues by childbirth and aging has been 
      considered as key factors in the development of the SUI. In this study, plasmid 
      DNA (pDNA; encoding for bFGF) complex-loaded poly(DL-lactic-co-glycolic acid) 
      (PLGA)/Pluronic F127 mixture dispersed with polycaprolactone (PCL) microspheres 
      was prepared as an injectable bioactive bulking agent that may provide bulking 
      effect (by PCL microspheres) and allow stimulation of the defect tissues around 
      urethra (by synthesis of bFGF from cells or tissues transfected by the pDNA 
      complex) for the effective treatment of SUI. From in vitro experiments, the pDNA 
      complex incorporated in the bulking agent was released in a sustained manner over 
      84 days (>/=80% of the initial loading amount). The pDNA complex was effectively 
      transfected into fibroblasts and the cells were continuously producing the target 
      protein, bFGF. From the in vivo study using hairless mice and Sprague-Dawley 
      rats, it was confirmed that the pDNA complex released from the bulking agent is 
      transfected into surrounding cells/tissue, and the cells/tissues synthesize 
      sufficient bFGF to regenerate smooth muscle with biological function around the 
      urethra. Basis on these results, the pDNA (encoding for bFGF) complex-loaded 
      PLGA/Pluronic F127 mixture dispersed with PCL microspheres can be a promising 
      bioactive bulking agent system for the fundamental cure of SUI.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Choi, Soo Jung
AU  - Choi SJ
AD  - Department of Advanced Materials, Hannam University, Yuseong Gu, Daejeon, 
      Republic of Korea.
FAU - Oh, Se Heang
AU  - Oh SH
FAU - Kim, In Gul
AU  - Kim IG
FAU - Chun, So Young
AU  - Chun SY
FAU - Lee, Ji Youl
AU  - Lee JY
FAU - Lee, Jin Ho
AU  - Lee JH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130329
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Animals
MH  - DNA/*metabolism
MH  - Disease Models, Animal
MH  - Female
MH  - Fibroblast Growth Factor 2/metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Injections
MH  - Mice
MH  - Muscle Contraction
MH  - Particle Size
MH  - Plasmids/*metabolism
MH  - Prosthesis Implantation
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Recovery of Function
MH  - Static Electricity
MH  - Subcutaneous Tissue/pathology
MH  - Urethra/pathology/*physiopathology
MH  - Urinary Incontinence/pathology/*physiopathology/*therapy
MH  - Urodynamics
EDAT- 2013/04/03 06:00
MHDA- 2013/10/23 06:00
CRDT- 2013/04/03 06:00
PHST- 2013/02/28 00:00 [received]
PHST- 2013/03/15 00:00 [accepted]
PHST- 2013/04/03 06:00 [entrez]
PHST- 2013/04/03 06:00 [pubmed]
PHST- 2013/10/23 06:00 [medline]
AID - S0142-9612(13)00355-4 [pii]
AID - 10.1016/j.biomaterials.2013.03.045 [doi]
PST - ppublish
SO  - Biomaterials. 2013 Jul;34(20):4766-76. doi: 10.1016/j.biomaterials.2013.03.045. 
      Epub 2013 Mar 29.